Дигидропиридиновые антагонисты кальция в лечении артериальной гипертензии: эффективность и безопасность фелодипина

1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
2. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиологический вестн. 2015; 1: 3–30. / Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiologicheskii vestn. 2015; 1: 3–30. [in Russian]
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–9.
5. Verdecchia P, Reboldi G, Angeli F et al. AngiotensinConverting Enzyme Inhibitorsand Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension 2005; 46: 386–92.
6. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.
7. Liu L, Zhang Y, Liu G et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157–72.
8. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
9. Poole-Wilson PA, Lubsen J, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–57.
10. Dalhof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindoprilas required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
11. Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium Medicum. 2006; 8 (11): 113–7. / Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Antagonisty kal'tsiia: sovremennye aspekty primeneniia v kardiologii. Consilium Medicum. 2006; 8 (11): 113–7. [in Russian]
12. Сидоренко Б.А., Преображенский Д.В. Применение антагонистов кальция в кардиологической практике. М.: Пресид, 1997. / Sidorenko B.A., Preobrazhenskii D.V. Primenenie antagonistov kal'tsiia v kardiologicheskoi praktike. M.: Presid, 1997. [in Russian]
13. Белоусов Ю.Б., Моисеев B.C., Лепахин В.К. Клиническая фармакология и терапия. Руководство для врачей. М.: Универсум паблишинг, 2000; с. 97–110, 150–2. / Belousov Iu.B., Moiseev B.C., Lepakhin V.K. Klinicheskaia farmakologiia i terapiia. Rukovodstvo dlia vrachei. M.: Universum pablishing, 2000; s. 97–110, 150–2. [in Russian]
14. Белоусов Ю.Б., Леонова М.В. Антагонисты кальция пролонгированного действия и сердечно-сосудистая заболеваемость: новые данные доказательной медицины. Кардиология. 2001; 4: 87–93. / Belousov Iu.B., Leonova M.V. Antagonisty kal'tsiia prolongirovannogo deistviia i serdechno-sosudistaia zabolevaemost': novye dannye dokazatel'noi meditsiny. Kardiologiia. 2001; 4: 87–93. [in Russian]
15. Wong ND, Teng W, Abrahamson D et al. Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: Rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS). Am J Cardiol 1995; 76 (17): 1239–42.
16. Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12 (2): 218–25.
17. Schmitz A. Acute renal effects of oral felodipine in normal man. Eur J Clin Pharmacol 1987; 32 (1): 17–22.
18. Lernfelt B, Landahl S, Johansson P et al. Haemodynamic and renal effects of felodipine in young and elderly subjects. Eur J Clin Pharmacol 1998; 54 (8): 595–601.
19. Hasselgren B, Edgar B, Johnsson G, Rönn O. The acute haemodynamic and renal effects of oral felodipine and ramipril in healthy subjects. Eur J Clin Pharmacol 1993; 45 (4): 327–32.
20. Huysmans FT, van Hamersvelt HW, Sluiter HE et al. Acute renal effects of felodipine in hypertensive patients with kidney disease. Kidney Int Suppl 1992; 36: S106–9.
21. Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16: 2158–65.
22. Ruggenenti P, Perna A, Loriga G et al. The REIN-2 Study Group. Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 2005; 365 (9463): 939–46.
23. Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs 2003; 63 (15): 1535–48.
24. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int 2007; 72 (12): 1429–47.
25. Sоrensen SS, Skovbon H, Eiskjaer H et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol Dial Transplant 1992; 7 (1): 69–78.
26. Pedersen EB, Madsen JK, Sorensen SS, Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney Int Suppl 1996; 55: S94–6.
27. Madsen JK, Sorensen SS, Hansen HE, Pedersen EB. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 1998; 13 (9): 2327–34.
28. Dietz JD, Du S, Bolten CW et al A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51 (3): 742–8.
29. Matsubara BB, Franco M, Janicki JS, Matsubara LS. Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. Brazil J Med Biol Res 2010; 43: 506–14.
30. Kaur M, Kaur K, Bedi GK et al. Effect of felodipine on the serum lipid profile of patients with hypertension. Ind J Cl Biochem 2000; 15 (2): 63–7.
31. Lehrl S, Grossel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study. Dtsch Med Wochenschr 2000; 125 (45): 1350–6.
32. Levy J, Zhu Z, Dunbar JC. The effect of global brain ischemia in normal and diabetic animals: the influence of calcium channel blockers. Endocrine 2004; 25 (2): 91–5.
33. Meyer FP. Felodipine in hypertensive patients with mild encephalopathies. Dtsch Med Wochenschr 2001; 126 (19): 577–8.
34. Naumović N, Slankamenac P, Filipović D et al. Effects of calcium antagonists on brain ischemia. Med Pregl 2011; 64 (5–6): 257–61.
35. Ito Y, Araki N. Calcium antagonists: current and future applications based on new evidence. Neuroprotective effect of calcium antagonists. Clin Calcium 2010; 20 (1): 83–8. doi: CliCa10018388
36. Bratel T, Hedenstierna G, Nyquist O, Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. Eur Respir J 1990; 3 (1): 46–54.
37. Sajkov D, McEvoy RD, Cowie RJ et al. Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonary disease. Chest 1993; 103 (5): 1354–61.
38. Sajkov D, Wang T, Frith PA et al. A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Chest 1997; 111 (6): 1622–30.
39. Liu L, Zhang Y, Liu G, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23 (12): 2157–72.
40. Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study Group. Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. J Hypertens 2010; 28 (10): 2016–25.
41. Brun J, Freberg L, Kronmann P et al. Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. J Cardiovasc Pharmacol 1990; 15 (Suppl. 4): S60–S64.
42. Weber MA, Goldberg AI, Faison EP et al. Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. Clin Pharmacol Ther 1994; 55 (3): 346–52.
43. Podjarny E, Korzets Z, Bernheim J. Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring. J Hum Hypertens 1996; 10 (Suppl. 3): S153–S156.
44. Antonicelli R, Omboni S, Giovanni DC et al. Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Drugs Aging 2002; 19 (7): 541–51.
45. Manzo BA, Matalka MS, Ravnan SL. Evaluation of a therapeutic conversion from amlodipine to felodipine. Pharmacotherapy 2003; 23: 1508–12.
46. Leenen FH, Coletta E. Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. J Cardiovasc Pharmacol 2010; 56 (6): 669–75.
47. Schaefer RM, Aldons PM, Burgess ED et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract 1998; 52 (6): 381–6.
48. Bicchi M, Vedovini G, Cappelli R et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998; 49 (5): 373–80.
49. Corradi L, Colombo G, Ravera E, Lotto A. Clinical interest of once-daily felodipine extended-release in patients with mixed and exertional angina. Results of a double-blind crossover study versus amlodipine. Clin Drug Invest 1995; 9: 324–33.
50. Агеев Ф.Т., Деев А.Д. Применение фелодипина в амбулаторной практике: оценка клинической эффективности и приверженности к лечению у больных с артериальной гипертензией. Кардиология. 2009; 49 (1): 30–3. / Ageev F.T., Deev A.D. Primenenie felodipina v ambulatornoi praktike: otsenka klinicheskoi effektivnosti i priverzhennosti k lecheniiu u bol'nykh s arterial'noi gipertenziei. Kardiologiia. 2009; 49 (1): 30–3. [in Russian]

________________________________________________

1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
2. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Kardiologicheskii vestn. 2015; 1: 3–30. [in Russian]
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–9.
5. Verdecchia P, Reboldi G, Angeli F et al. AngiotensinConverting Enzyme Inhibitorsand Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension 2005; 46: 386–92.
6. Mancia G, Laurent S, Agabiti-Rosei E et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.
7. Liu L, Zhang Y, Liu G et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157–72.
8. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–25.
9. Poole-Wilson PA, Lubsen J, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–57.
10. Dalhof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindoprilas required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
11. Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Antagonisty kal'tsiia: sovremennye aspekty primeneniia v kardiologii. Consilium Medicum. 2006; 8 (11): 113–7. [in Russian]
12. Sidorenko B.A., Preobrazhenskii D.V. Primenenie antagonistov kal'tsiia v kardiologicheskoi praktike. M.: Presid, 1997. [in Russian]
13. Belousov Iu.B., Moiseev B.C., Lepakhin V.K. Klinicheskaia farmakologiia i terapiia. Rukovodstvo dlia vrachei. M.: Universum pablishing, 2000; s. 97–110, 150–2. [in Russian]
14. Belousov Iu.B., Leonova M.V. Antagonisty kal'tsiia prolongirovannogo deistviia i serdechno-sosudistaia zabolevaemost': novye dannye dokazatel'noi meditsiny. Kardiologiia. 2001; 4: 87–93. [in Russian]
15. Wong ND, Teng W, Abrahamson D et al. Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: Rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS). Am J Cardiol 1995; 76 (17): 1239–42.
16. Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12 (2): 218–25.
17. Schmitz A. Acute renal effects of oral felodipine in normal man. Eur J Clin Pharmacol 1987; 32 (1): 17–22.
18. Lernfelt B, Landahl S, Johansson P et al. Haemodynamic and renal effects of felodipine in young and elderly subjects. Eur J Clin Pharmacol 1998; 54 (8): 595–601.
19. Hasselgren B, Edgar B, Johnsson G, Rönn O. The acute haemodynamic and renal effects of oral felodipine and ramipril in healthy subjects. Eur J Clin Pharmacol 1993; 45 (4): 327–32.
20. Huysmans FT, van Hamersvelt HW, Sluiter HE et al. Acute renal effects of felodipine in hypertensive patients with kidney disease. Kidney Int Suppl 1992; 36: S106–9.
21. Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16: 2158–65.
22. Ruggenenti P, Perna A, Loriga G et al. The REIN-2 Study Group. Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 2005; 365 (9463): 939–46.
23. Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs 2003; 63 (15): 1535–48.
24. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int 2007; 72 (12): 1429–47.
25. Sоrensen SS, Skovbon H, Eiskjaer H et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol Dial Transplant 1992; 7 (1): 69–78.
26. Pedersen EB, Madsen JK, Sorensen SS, Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney Int Suppl 1996; 55: S94–6.
27. Madsen JK, Sorensen SS, Hansen HE, Pedersen EB. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 1998; 13 (9): 2327–34.
28. Dietz JD, Du S, Bolten CW et al A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51 (3): 742–8.
29. Matsubara BB, Franco M, Janicki JS, Matsubara LS. Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. Brazil J Med Biol Res 2010; 43: 506–14.
30. Kaur M, Kaur K, Bedi GK et al. Effect of felodipine on the serum lipid profile of patients with hypertension. Ind J Cl Biochem 2000; 15 (2): 63–7.
31. Lehrl S, Grossel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study. Dtsch Med Wochenschr 2000; 125 (45): 1350–6.
32. Levy J, Zhu Z, Dunbar JC. The effect of global brain ischemia in normal and diabetic animals: the influence of calcium channel blockers. Endocrine 2004; 25 (2): 91–5.
33. Meyer FP. Felodipine in hypertensive patients with mild encephalopathies. Dtsch Med Wochenschr 2001; 126 (19): 577–8.
34. Naumović N, Slankamenac P, Filipović D et al. Effects of calcium antagonists on brain ischemia. Med Pregl 2011; 64 (5–6): 257–61.
35. Ito Y, Araki N. Calcium antagonists: current and future applications based on new evidence. Neuroprotective effect of calcium antagonists. Clin Calcium 2010; 20 (1): 83–8. doi: CliCa10018388
36. Bratel T, Hedenstierna G, Nyquist O, Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. Eur Respir J 1990; 3 (1): 46–54.
37. Sajkov D, McEvoy RD, Cowie RJ et al. Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonary disease. Chest 1993; 103 (5): 1354–61.
38. Sajkov D, Wang T, Frith PA et al. A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD. Chest 1997; 111 (6): 1622–30.
39. Liu L, Zhang Y, Liu G, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23 (12): 2157–72.
40. Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study Group. Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. J Hypertens 2010; 28 (10): 2016–25.
41. Brun J, Freberg L, Kronmann P et al. Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. J Cardiovasc Pharmacol 1990; 15 (Suppl. 4): S60–S64.
42. Weber MA, Goldberg AI, Faison EP et al. Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. Clin Pharmacol Ther 1994; 55 (3): 346–52.
43. Podjarny E, Korzets Z, Bernheim J. Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring. J Hum Hypertens 1996; 10 (Suppl. 3): S153–S156.
44. Antonicelli R, Omboni S, Giovanni DC et al. Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Drugs Aging 2002; 19 (7): 541–51.
45. Manzo BA, Matalka MS, Ravnan SL. Evaluation of a therapeutic conversion from amlodipine to felodipine. Pharmacotherapy 2003; 23: 1508–12.
46. Leenen FH, Coletta E. Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. J Cardiovasc Pharmacol 2010; 56 (6): 669–75.
47. Schaefer RM, Aldons PM, Burgess ED et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract 1998; 52 (6): 381–6.
48. Bicchi M, Vedovini G, Cappelli R et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998; 49 (5): 373–80.
49. Corradi L, Colombo G, Ravera E, Lotto A. Clinical interest of once-daily felodipine extended-release in patients with mixed and exertional angina. Results of a double-blind crossover study versus amlodipine. Clin Drug Invest 1995; 9: 324–33.
50. Ageev F.T., Deev A.D. Primenenie felodipina v ambulatornoi praktike: otsenka klinicheskoi effektivnosti i priverzhennosti k lecheniiu u bol'nykh s arterial'noi gipertenziei. Kardiologiia. 2009; 49 (1): 30–3. [in Russian]

О.Д.Остроумова*1,2, Е.А.Смолярчук2, И.И.Копченов1

1 ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ostroumova.olga@mail.ru

________________________________________________